RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR T-Cell therapy aims to outperform current treatment for aggressive lymphoma
Disease control Recruiting nowThis phase 3 trial tests whether a new CAR T-cell therapy, KITE-753, works better than the current standard, axicabtagene ciloleucel (axi-cel), for adults with large B-cell lymphoma that returned or didn't respond to first treatment. About 550 participants will receive one infusi…
Matched conditions: RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug combo shows promise for hard-to-treat lymphoma
Disease control Recruiting nowThis study tests a combination of the immunotherapy drug epcoritamab with standard chemotherapy (GDP) in 32 adults whose large B-cell lymphoma has returned or not responded to treatment. The goal is to see if the combo can shrink tumors enough to allow for a stem cell transplant …
Matched conditions: RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Dipenkumar Modi • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New combo may boost CAR-T success in tough lymphoma
Disease control Recruiting nowThis study tests whether giving two drugs (loncastuximab tesirine and rituximab) before standard CAR-T cell therapy can improve outcomes for adults with large B-cell lymphoma that has come back or not responded to treatment. About 29 participants will receive this bridging therap…
Matched conditions: RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising cocktail targets deadly lymphoma mutation
Disease control Recruiting nowThis phase 2 trial tests a combination of three drugs—glofitamab, a PD-1 inhibitor, and lenalidomide—in 24 adults with relapsed or refractory large B-cell lymphoma that has a TP53 gene mutation. The goal is to see if this mix can shrink tumors or make them disappear. The study is…
Matched conditions: RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC